Back to Search
Start Over
Rebound after discontinuation of teriflunomide in patients with multiple sclerosis: 2 case reports.
- Source :
-
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2020 Jun; Vol. 41, pp. 102017. Date of Electronic Publication: 2020 Feb 24. - Publication Year :
- 2020
-
Abstract
- Teriflunomide is an oral first-line disease modifying treatment (DMT) for patients with relapsing-remitting multiple sclerosis (RRMS). It can take up to two years to achieve systemic clearance of teriflunomide to an acceptable level, but this washout period may be accelerated by administration of cholestyramine. Relapse of multiple sclerosis (MS) during washout of teriflunomide or other first-line DMT is not as common. We report two patients with RRMS who experienced a relapse after the accelerated elimination period (AEP) of teriflunomide and confirmation of negative plasmatic levels (<0.02 µg/ml). In cases of risk of MS activity, we should not wait for teriflunomide negative plasmatic levels confirmation before starting the next DMT to reduce the risk of relapse.<br />Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest<br /> (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Subjects :
- Adult
Anion Exchange Resins administration & dosage
Cholestyramine Resin administration & dosage
Crotonates blood
Female
Humans
Hydroxybutyrates
Immunologic Factors blood
Male
Nitriles
Recurrence
Toluidines blood
Crotonates pharmacokinetics
Immunologic Factors pharmacokinetics
Multiple Sclerosis, Relapsing-Remitting drug therapy
Multiple Sclerosis, Relapsing-Remitting physiopathology
Toluidines pharmacokinetics
Subjects
Details
- Language :
- English
- ISSN :
- 2211-0356
- Volume :
- 41
- Database :
- MEDLINE
- Journal :
- Multiple sclerosis and related disorders
- Publication Type :
- Report
- Accession number :
- 32120027
- Full Text :
- https://doi.org/10.1016/j.msard.2020.102017